MENLO PARK, Calif.--(BUSINESS WIRE)--May 18, 2006--SRI International, an independent nonprofit research and development organization, today announced it has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for $931,000 to develop an oral formulation for calcium DTPA and zinc DTPA, two drugs approved for decorporation. Decorporation agents increase the rate of elimination or excretion of absorbed, inhaled or ingested radioactive contaminants.
